Observational Study to Evaluate the Effectiveness of Phosphatidylserine, Bacopa E.S., Choline, Homotaurine, Resveratrol, Group B Vitamins and Folic Acid Supplementation (Cogitix ®) In the Control of Cognitive Disorders.

Considering that in a growing elderly population mild cognitive impairment (MCI) are increasing in prevalence worldwide and that currently no high-quality evidence exists to support pharmacologic treatments, there is a need to find new therapeutic approaches, including natural ones, to reduce the risk of developing cognitive deficits. The aim of this study is to evaluate the effectiveness of Phosphatidylserine, Bacopa E.S., Choline, Homotaurine, Resveratrol, Group B vitamins and Folic acid supplementation (Cogitix) in maintaining and/or improving cognitive performances . Thirty consecutive adult patients attending at ASP S. Margherita Pavia – University of Pavia with MCI score between 24 and 28 or preMCI 27-28 were treated with Cogitix, 1 cp/day , for 3 months. Cognitive status assessment will be evaluated at baseline and at the end of treatment using MMSE test. MCI medium value at baseline was 24,9 and after 3 months has become 25,8 and that in 67% of patients there was an improvement , although not statistically significant, by one or two points in the score. In preMCI status there was an improvement by one point in the score in 33% of patients. The study also confirmed that Cogitix-based products are able, in a short period of treatment, to improve blood parameters such as cholesterol, triglycerides and homocysteine. Treatment was well tolerated (on a numerical scale from 1 to 10 the average score was 9,5. The compliance of patients was optimal, no side effect was reported and no weight gain occurred. Data from our study are encouraging to be confirmed by further investigations considering higher dosages, longer treatment periods and more selected population.